Leonardo Minelli Grazioli

Leonardo Minelli Grazioli

Auto-generated profile, based on publicly available information

Leonardo Minelli Grazioli

Department of Gastroenterology and Endoscopy Fondazione Poliambulanza Istituto Ospedaliero Brescia Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2014 in Gut
Verified
Journal Article
Closed access
PDF file
CSCristiano Spada
Cristiano Spada
CHCesare Hassan
Cesare Hassan
BBBrunella Barbaro
Brunella Barbaro
FIFranco Iafrate
Franco Iafrate
PCPaola Cesaro
Paola Cesaro
GCGuido Costamagna
Guido Costamagna
Objective In case of incomplete colonoscopy, several radiologic methods have traditionally been used, but more recently, capsule endoscopy was also shown to be accurate. Aim of this study was to compare colon capsule endoscopy (CCE) and CT colonography (CTC) in a prospective cohort of patients with incomplete colonoscopy. Design Consecutive patients with a previous incomplete colonoscopy underwent CCE and CTC followed by colonoscopy in case of positive findings on either test (polyps/mass lesions ≥6 mm). Clinical follow-up was performed in the other cases to rule out missed cancer. CTC was performed after colon capsule excretion or 10–12 h postingestion. Since the gold standard colonoscopy was performed only in positive cases, diagnostic yield and positive predictive values of CCE and CTC were used as study end-points. Results 100 patients were enrolled. CCE and CTC were able to achieve complete colonic evaluation in 98% of cases. In a per-patient analysis for polyps ≥6 mm, CCE detected 24 patients (24.5%) and CTC 12 patients (12.2%). The relative sensitivity of CCE compared to CTC was 2.0 (95% CI 1.34 to 2.98), indicating a significant increase in sensitivity for lesions ≥6 mm. Of larger polyps (≥10 mm), these values were 5.1% for CCE and 3.1% for CTC (relative sensitivity: 1.67 (95% CI 0.69 to 4.00)). Positive predictive values for polyps ≥6 mm and ≥10 mm were 96% and 85.7%, and 83.3% and 100% for CCE and CTC, respectively. No missed cancer occurred at clinical follow-up of a mean of 20 months. Conclusions CCE and CTC were of comparable efficacy in completing colon evaluation after incomplete colonoscopy; the overall diagnostic yield of colon capsule was superior to CTC. Trial registration number NCT01525940.

15 February 2012 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
CSCristiano Spada
Cristiano Spada
FVFabio De Vincentis
Fabio De Vincentis
PCPaola Cesaro
Paola Cesaro
CHCesare Hassan
Cesare Hassan
MRMaria Elena Riccioni
Maria Elena Riccioni
GCGuido Costamagna
Guido Costamagna
PillCam COLON capsule endoscopy (CCE) (Given Imaging Ltd, Yoqneam, Israel) is one of the most recent diagnostic, endoscopic technologies designed to explore the colon. CCE is a noninvasive, patient-friendly technique that is able to explore the colon without requiring sedation and air insufflation. The first generation of CCE was released onto the market in 2006 and although it generated great enthusiasm, it showed suboptimal accuracy. Recently, a second-generation system (PillCam COLON 2) (CCE-2) has been developed to increase sensitivity for colorectal polyp detection. In this review, accuracy and safety data for CCE-2 are analyzed.

30 May 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
SMSebastian Manuel Milluzzo
Sebastian Manuel Milluzzo
PCPaola Cesaro
Paola Cesaro
LGLeonardo Minelli Grazioli
Leonardo Minelli Grazioli
NONicola Olivari
Nicola Olivari
CSCristiano Spada
Cristiano Spada
The present manuscript aims to review the history, recent advances, evidence, and challenges of artificial intelligence (AI) in colonoscopy. Although it is mainly focused on polyp detection and characterization, it also considers other potential applications (i.e., inflammatory bowel disease) and future perspectives. Some of the most recent algorithms show promising results that are similar to human expert performance. The integration of AI in routine clinical practice will be challenging, with significant issues to overcome (i.e., regulatory, reimbursement). Medico-legal issues will also need to be addressed. With the exception of an AI system that is already available in selected countries (GI Genius; Medtronic, Minneapolis, MN, USA), the majority of the technology is still in its infancy and has not yet been proven to reach a sufficient diagnostic performance to be adopted in the clinical practice. However, larger players will enter the arena of AI in the next few months.

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
CSCristiano Spada
Cristiano Spada
FBFederico Barbaro
Federico Barbaro
GAGianluca Andrisani
Gianluca Andrisani
LGLeonardo Minelli Grazioli
Leonardo Minelli Grazioli
CHCesare Hassan
Cesare Hassan
GCGuido Costamagna
Guido Costamagna
Colonoscopy is usually perceived as an invasive and potentially painful procedure, being also affected by a small, but definite, risk of major complications (cardiopulmonary complications, perforation, hemorrhage) and even mortality. To improve both acceptability and safety, PillCam Colon Capsule Endoscopy (CCE) (Given Imaging Ltd, Yoqneam, Israel) has been developed. CCE represents a non-invasive technique that is able to explore the colon without sedation and air insufflation. The Second Generation of Colon Capsule Endoscopy (PillCam Colon 2) (CCE-2) was proven to be an accurate tool to detect colonic neoplastic lesions when used in average risk individuals. To date, the evidence supports the use of CCE-2 in case of colonoscopy failure, in patients unwilling to perform colonoscopy and when colonoscopy is contraindicated. Other potential applications, such as colorectal cancer screening or diagnostic surveillance of inflammatory bowel disease need to be clarified. In this paper, the current “state of the art”, potential application of CCE and future needs are evaluated.

14 January 2025 in Digestive and Liver Disease
Verified
Journal Article
Closed access
CSCristiano Spada
Cristiano Spada
DSDaniele Salvi
Daniele Salvi
CFClarissa Ferrari
Clarissa Ferrari
CHC. Hassan
C. Hassan
FBFederico Barbaro
Federico Barbaro
GCG. Costamagna
G. Costamagna

21 January 2026 in United European Gastroenterology Journal
Verified
Journal Article
Open access
CSCristiano Spada
Cristiano Spada
PCPaola Cesaro
Paola Cesaro
LFLorenzo Fuccio
Lorenzo Fuccio
DSDaniele Salvi
Daniele Salvi
CFClarissa Ferrari
Clarissa Ferrari
Guido CostamagnaGuido Costamagna
Guido Costamagna
Background: The fecal immunochemical test (FIT) is widely implemented as a first‐line tool in organized colorectal cancer (CRC) screening programs, including Italy. Following a positive FIT, colonoscopy is recommended. Computer‐aided detection (CADe) systems have the potential to enhance adenoma detection, particularly in FIT‐positive populations where identifying advanced adenomas is critical for cancer prevention. This study evaluated the diagnostic performance of CADe‐assisted colonoscopy versus standard colonoscopy (SC) in a FIT‐based screening cohort. Methods: In this multicenter, randomized controlled trial, patients with a positive FIT result were randomized to undergo either CADe‐assisted or standard colonoscopy. The primary endpoint was the advanced adenoma detection rate (AADR). Secondary endpoints included overall adenoma detection rate (ADR), adenomas per colonoscopy (APC), and mean withdrawal time (WT). Results: Of 1077 patients enrolled, 68 were excluded due to inadequate bowel preparation, leaving 1009 patients for analysis (CADe: n = 506; SC: n = 503). AADR was comparable between the groups (21.3% vs. 20.5%, p = 0.794). However, CADe significantly improved ADR (67.6% vs. 59.8%, p = 0.012) and APC (1.82 ± 2.12 vs. 1.34 ± 1.81, p < 0.001). Mean WT was longer in the CADe group (17.10 ± 8.28 min vs. 16.13 ± 8.28 min, p = 0.016). Conclusions: In a FIT‐based organized CRC screening setting, CADe did not enhance detection of AADR with a modest increase in withdrawal time. NCT04441580.